Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates
Fifteen years after the Human Genome Project, genomic variants have been associated with disease risk and outcomes in thousands of publications. Based largely on this literature, physicians who order genetic testing receive reports that indicate whether "pathogenic" variants have been foun...
Gespeichert in:
| Veröffentlicht in: | JAMA : the journal of the American Medical Association 2016-03, Vol.315 (12), p.1233-1234 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1234 |
|---|---|
| container_issue | 12 |
| container_start_page | 1233 |
| container_title | JAMA : the journal of the American Medical Association |
| container_volume | 315 |
| creator | Manrai, Arjun K Ioannidis, John P. A Kohane, Isaac S |
| description | Fifteen years after the Human Genome Project, genomic variants have been associated with disease risk and outcomes in thousands of publications. Based largely on this literature, physicians who order genetic testing receive reports that indicate whether "pathogenic" variants have been found. This information aspires to form the basis of precision medicine. Knowledge of pathogenic variants is expected to lead to optimal management of individuals as well as their families through recommendations about further screening, prevention, and tailored treatment. However, some suggest that current information on pathogenic variants is typically impossible to act on. This information is often unreliable and generally does not provide a quantitative measure of risk. The information the physician usually needs is the likelihood of disease among patients with the variant (penetrance), and an assessment of whether the genetic profile requires action or not. Here, Manral and Ioannidis discuss sharing the underlying data of genetic testing to develop more precise disease risk estimates and understand whether physicians should act on them. |
| doi_str_mv | 10.1001/jama.2016.1519 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1805498695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2498853</ama_id><sourcerecordid>1775632024</sourcerecordid><originalsourceid>FETCH-LOGICAL-a330t-8f34aae723622023658faaf2bc73d591db5b5e0ebbd316e8cf8d01348b7ceaf3</originalsourceid><addsrcrecordid>eNqFkb1PwzAQxS0EoqWwMjCgSCwsKf5MbDYUtQVRiQ91t5zEAZckLrGD1P8eR4UOLNzgG-73Tu_8ADhHcIogRDdr1agphiiZIobEARgjRnhMmOCHYAyh4HFKOR2BE-fWMBQi6TEY4URgJjAdg8esNq0pVB0tdGsbU7jbaN7ZJnpW_t2-6TAzfhtltTKNi7yNXnrVeuOVN186ejXuI5o5bxrltTsFR5WqnT776ROwms9W2X28fFo8ZHfLWBECfcwrQpXSKSYJxjC8jFdKVTgvUlIygcqc5UxDneclQYnmRcXL4JvyPC20qsgEXO_Wbjr72WvnZWNcoetatdr2TiIOGRU8Eex_NE1ZQoIJGtCrP-ja9l0b7ggUHz43oTBQ0x1VdNa5Tldy04Xju61EUA6ByCEQOQQiB00QXP6s7fNGl3v8N4EAXOyAQbefBv-cEfINnfeOMQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781519640</pqid></control><display><type>article</type><title>Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Manrai, Arjun K ; Ioannidis, John P. A ; Kohane, Isaac S</creator><creatorcontrib>Manrai, Arjun K ; Ioannidis, John P. A ; Kohane, Isaac S</creatorcontrib><description>Fifteen years after the Human Genome Project, genomic variants have been associated with disease risk and outcomes in thousands of publications. Based largely on this literature, physicians who order genetic testing receive reports that indicate whether "pathogenic" variants have been found. This information aspires to form the basis of precision medicine. Knowledge of pathogenic variants is expected to lead to optimal management of individuals as well as their families through recommendations about further screening, prevention, and tailored treatment. However, some suggest that current information on pathogenic variants is typically impossible to act on. This information is often unreliable and generally does not provide a quantitative measure of risk. The information the physician usually needs is the likelihood of disease among patients with the variant (penetrance), and an assessment of whether the genetic profile requires action or not. Here, Manral and Ioannidis discuss sharing the underlying data of genetic testing to develop more precise disease risk estimates and understand whether physicians should act on them.</description><identifier>ISSN: 0098-7484</identifier><identifier>EISSN: 1538-3598</identifier><identifier>DOI: 10.1001/jama.2016.1519</identifier><identifier>PMID: 26925924</identifier><identifier>CODEN: JAMAAP</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Clinical outcomes ; Genetic Predisposition to Disease ; Genetic Testing - standards ; Genetic Variation ; Genomics - standards ; Hemochromatosis - genetics ; Heterozygote ; Humans ; Information Dissemination ; Laboratories - standards ; Pathogenesis ; Penetrance ; Precision Medicine - standards ; Qualitative research ; Risk assessment ; Risk Assessment - standards ; Selection Bias ; Uncertainty</subject><ispartof>JAMA : the journal of the American Medical Association, 2016-03, Vol.315 (12), p.1233-1234</ispartof><rights>Copyright American Medical Association Mar 22-Mar 29, 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jama/articlepdf/10.1001/jama.2016.1519$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2016.1519$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,314,776,780,3327,27901,27902,76231,76234</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26925924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Manrai, Arjun K</creatorcontrib><creatorcontrib>Ioannidis, John P. A</creatorcontrib><creatorcontrib>Kohane, Isaac S</creatorcontrib><title>Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates</title><title>JAMA : the journal of the American Medical Association</title><addtitle>JAMA</addtitle><description>Fifteen years after the Human Genome Project, genomic variants have been associated with disease risk and outcomes in thousands of publications. Based largely on this literature, physicians who order genetic testing receive reports that indicate whether "pathogenic" variants have been found. This information aspires to form the basis of precision medicine. Knowledge of pathogenic variants is expected to lead to optimal management of individuals as well as their families through recommendations about further screening, prevention, and tailored treatment. However, some suggest that current information on pathogenic variants is typically impossible to act on. This information is often unreliable and generally does not provide a quantitative measure of risk. The information the physician usually needs is the likelihood of disease among patients with the variant (penetrance), and an assessment of whether the genetic profile requires action or not. Here, Manral and Ioannidis discuss sharing the underlying data of genetic testing to develop more precise disease risk estimates and understand whether physicians should act on them.</description><subject>Clinical outcomes</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetic Testing - standards</subject><subject>Genetic Variation</subject><subject>Genomics - standards</subject><subject>Hemochromatosis - genetics</subject><subject>Heterozygote</subject><subject>Humans</subject><subject>Information Dissemination</subject><subject>Laboratories - standards</subject><subject>Pathogenesis</subject><subject>Penetrance</subject><subject>Precision Medicine - standards</subject><subject>Qualitative research</subject><subject>Risk assessment</subject><subject>Risk Assessment - standards</subject><subject>Selection Bias</subject><subject>Uncertainty</subject><issn>0098-7484</issn><issn>1538-3598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkb1PwzAQxS0EoqWwMjCgSCwsKf5MbDYUtQVRiQ91t5zEAZckLrGD1P8eR4UOLNzgG-73Tu_8ADhHcIogRDdr1agphiiZIobEARgjRnhMmOCHYAyh4HFKOR2BE-fWMBQi6TEY4URgJjAdg8esNq0pVB0tdGsbU7jbaN7ZJnpW_t2-6TAzfhtltTKNi7yNXnrVeuOVN186ejXuI5o5bxrltTsFR5WqnT776ROwms9W2X28fFo8ZHfLWBECfcwrQpXSKSYJxjC8jFdKVTgvUlIygcqc5UxDneclQYnmRcXL4JvyPC20qsgEXO_Wbjr72WvnZWNcoetatdr2TiIOGRU8Eex_NE1ZQoIJGtCrP-ja9l0b7ggUHz43oTBQ0x1VdNa5Tldy04Xju61EUA6ByCEQOQQiB00QXP6s7fNGl3v8N4EAXOyAQbefBv-cEfINnfeOMQ</recordid><startdate>20160322</startdate><enddate>20160322</enddate><creator>Manrai, Arjun K</creator><creator>Ioannidis, John P. A</creator><creator>Kohane, Isaac S</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QP</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20160322</creationdate><title>Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates</title><author>Manrai, Arjun K ; Ioannidis, John P. A ; Kohane, Isaac S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a330t-8f34aae723622023658faaf2bc73d591db5b5e0ebbd316e8cf8d01348b7ceaf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Clinical outcomes</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetic Testing - standards</topic><topic>Genetic Variation</topic><topic>Genomics - standards</topic><topic>Hemochromatosis - genetics</topic><topic>Heterozygote</topic><topic>Humans</topic><topic>Information Dissemination</topic><topic>Laboratories - standards</topic><topic>Pathogenesis</topic><topic>Penetrance</topic><topic>Precision Medicine - standards</topic><topic>Qualitative research</topic><topic>Risk assessment</topic><topic>Risk Assessment - standards</topic><topic>Selection Bias</topic><topic>Uncertainty</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Manrai, Arjun K</creatorcontrib><creatorcontrib>Ioannidis, John P. A</creatorcontrib><creatorcontrib>Kohane, Isaac S</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>JAMA : the journal of the American Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Manrai, Arjun K</au><au>Ioannidis, John P. A</au><au>Kohane, Isaac S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates</atitle><jtitle>JAMA : the journal of the American Medical Association</jtitle><addtitle>JAMA</addtitle><date>2016-03-22</date><risdate>2016</risdate><volume>315</volume><issue>12</issue><spage>1233</spage><epage>1234</epage><pages>1233-1234</pages><issn>0098-7484</issn><eissn>1538-3598</eissn><coden>JAMAAP</coden><abstract>Fifteen years after the Human Genome Project, genomic variants have been associated with disease risk and outcomes in thousands of publications. Based largely on this literature, physicians who order genetic testing receive reports that indicate whether "pathogenic" variants have been found. This information aspires to form the basis of precision medicine. Knowledge of pathogenic variants is expected to lead to optimal management of individuals as well as their families through recommendations about further screening, prevention, and tailored treatment. However, some suggest that current information on pathogenic variants is typically impossible to act on. This information is often unreliable and generally does not provide a quantitative measure of risk. The information the physician usually needs is the likelihood of disease among patients with the variant (penetrance), and an assessment of whether the genetic profile requires action or not. Here, Manral and Ioannidis discuss sharing the underlying data of genetic testing to develop more precise disease risk estimates and understand whether physicians should act on them.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>26925924</pmid><doi>10.1001/jama.2016.1519</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0098-7484 |
| ispartof | JAMA : the journal of the American Medical Association, 2016-03, Vol.315 (12), p.1233-1234 |
| issn | 0098-7484 1538-3598 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1805498695 |
| source | MEDLINE; American Medical Association Journals |
| subjects | Clinical outcomes Genetic Predisposition to Disease Genetic Testing - standards Genetic Variation Genomics - standards Hemochromatosis - genetics Heterozygote Humans Information Dissemination Laboratories - standards Pathogenesis Penetrance Precision Medicine - standards Qualitative research Risk assessment Risk Assessment - standards Selection Bias Uncertainty |
| title | Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T21%3A53%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Genomics:%20From%20Pathogenicity%20Claims%20to%20Quantitative%20Risk%20Estimates&rft.jtitle=JAMA%20:%20the%20journal%20of%20the%20American%20Medical%20Association&rft.au=Manrai,%20Arjun%20K&rft.date=2016-03-22&rft.volume=315&rft.issue=12&rft.spage=1233&rft.epage=1234&rft.pages=1233-1234&rft.issn=0098-7484&rft.eissn=1538-3598&rft.coden=JAMAAP&rft_id=info:doi/10.1001/jama.2016.1519&rft_dat=%3Cproquest_cross%3E1775632024%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781519640&rft_id=info:pmid/26925924&rft_ama_id=2498853&rfr_iscdi=true |